<DOC>
	<DOCNO>NCT01594255</DOCNO>
	<brief_summary>This study design compliance ICH-E14 guideline 2005 evaluate QT/QTc interval prolongation proarrhythmic potential non-antiarrhythmic drug .</brief_summary>
	<brief_title>CAEB071 Thorough QTc Study Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject age 18 50 year ( include ) age include , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Smokers tobacco product user ( previous 3 month ) . Use prescription drug , herbal supplement , within four ( 4 ) week prior initial dosing , and/or overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within two ( 2 ) week prior initial dosing . A marked baseline prolongation QT/QTcF interval Presence clinically significant illness Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>QT interval</keyword>
	<keyword>ECG</keyword>
	<keyword>QT/QTc interval prolongation proarrhythmic potential non-antiarrhythmic drug</keyword>
</DOC>